
Opinion|Videos|September 23, 2024
Data from LEVEL UP Trial with Upadacitnib in Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss Level Up data with upadacitinib that were recently presented at RAD 2024.
- What are clinical implications of these data for everyday practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5
























































